» Articles » PMID: 29446616

New Mechanism for Release of Endosomal Contents: Osmotic Lysis Via Nigericin-Mediated K/H Exchange

Overview
Journal Bioconjug Chem
Specialty Biochemistry
Date 2018 Feb 16
PMID 29446616
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Although peptides, antibodies/antibody fragments, siRNAs, antisense DNAs, enzymes, and aptamers are all under development as possible therapeutic agents, the breadth of their applications has been severely compromised by their inability to reach intracellular targets. Thus, while macromolecules can often enter cells by receptor-mediated endocytosis, their missions frequently fail due to an inability to escape their entrapping endosomes. In this paper, we describe a general method for promoting release of any biologic material from any entrapping endosome. The strategy relies on the fact that all nascent endosomes contain extracellular (Na-enriched) medium, but are surrounded by intracellular (K-enriched) fluid in the cytoplasm. Osmotic swelling and rupture of endosomes will therefore be facilitated if the flow of K down its concentration gradient from the cytosol into the endosome can be facilitated without allowing downhill flow of Na from the endosome into the cytosol. While any K selective ionophore can promote the K specific influx, the ideal K ionophore will also exchange influxed K for an osmotically inactive proton (H) in order to prevent buildup of an electrical potential that would rapidly halt K influx. The only ionophore that catalyzes this exchange of K for H efficiently is nigericin. We demonstrate here that ligand-targeted delivery of nigericin into endosomes that contain an otherwise impermeable fluorescent dye can augment release of the dye into the cell cytosol via swelling/bursting of the entrapping endosomes. We further show that nigericin-facilitated escape of a folate-targeted luciferase siRNA conjugate from its entrapping endosomes promotes rapid suppression of the intended luciferase reporter gene. Taken together, we propose that ionophore-catalyzed entry of K into endosomal compartments can promote the release of otherwise impermeable contents from their encapsulating endosomes.

Citing Articles

Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy.

Tripathy R, Pande A Pharm Res. 2025; 42(2):219-236.

PMID: 39953265 DOI: 10.1007/s11095-025-03829-z.


Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent.

Abdelaal A, Sohal I, Iyer S, Sudarshan K, Orellana E, Ozcan K Mol Ther Nucleic Acids. 2024; 35(2):102193.

PMID: 38745855 PMC: 11091501. DOI: 10.1016/j.omtn.2024.102193.


Preparing and Evaluating the Stability of Therapeutically Relevant Oligonucleotide Duplexes.

Iyer S, Kasinski A Bio Protoc. 2024; 14(8):e4975.

PMID: 38686344 PMC: 11056005. DOI: 10.21769/BioProtoc.4975.


The Parkinson's disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress.

McCarron K, Elcocks H, Mortiboys H, Urbe S, Clague M Biochem J. 2024; 481(4):265-278.

PMID: 38299383 PMC: 10903469. DOI: 10.1042/BCJ20230492.


A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.

Abdelaal A, Sohal I, Iyer S, Sudarshan K, Kothandaraman H, Lanman N Oncogene. 2023; 42(40):2985-2999.

PMID: 37666938 PMC: 10541324. DOI: 10.1038/s41388-023-02801-8.


References
1.
Harold F, Altendorf K, Hirata H . Probing membrane transport mechanisms with inophores. Ann N Y Acad Sci. 1974; 235(0):149-60. DOI: 10.1111/j.1749-6632.1974.tb43264.x. View

2.
Selbo P, Sandvig K, Kirveliene V, Berg K . Release of gelonin from endosomes and lysosomes to cytosol by photochemical internalization. Biochim Biophys Acta. 2000; 1475(3):307-13. DOI: 10.1016/s0304-4165(00)00082-9. View

3.
Sabharanjak S, Mayor S . Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev. 2004; 56(8):1099-109. DOI: 10.1016/j.addr.2004.01.010. View

4.
Vlahov I, Leamon C . Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem. 2012; 23(7):1357-69. DOI: 10.1021/bc2005522. View

5.
Zhang Y, Wang F . Carbohydrate drugs: current status and development prospect. Drug Discov Ther. 2015; 9(2):79-87. DOI: 10.5582/ddt.2015.01028. View